Title

Use of granulocyte colony-stimulating factor during pregnancy in women with chronic neutropenia

UMMS Affiliation

Department of Pediatrics, Division of Hematology/Oncology

Date

1-1-2015

Document Type

Article

Disciplines

Female Urogenital Diseases and Pregnancy Complications | Hematology | Hemic and Lymphatic Diseases | Maternal and Child Health | Obstetrics and Gynecology | Pediatrics | Women's Health

Abstract

OBJECTIVE: To report outcomes associated with the administration of granulocyte colony-stimulating factor (G-CSF) to women with chronic neutropenia during pregnancy.

METHODS: We conducted an observational study of women of childbearing potential with congenital, cyclic, idiopathic, or autoimmune neutropenia enrolled in the Severe Chronic Neutropenia International Registry to determine outcomes of pregnancies, without and with chronic G-CSF therapy, 1999-2014. Treatment decisions were made by the patients' personal physicians. A research nurse conducted telephone interviews of all enrolled U.S. women of childbearing potential using a standard questionnaire. Comparisons used Fisher's exact test analysis and Student's t test.

RESULTS: One hundred seven women reported 224 pregnancies, 124 without G-CSF therapy and 100 on chronic G-CSF therapy (median dose 1.0 micrograms/kg per day, range 0.02-8.6 micrograms/kg per day). There were no significant differences in adverse events between the groups considering all pregnancies or individual mothers, for example, spontaneous terminations (all pregnancies: no G-CSF in 27/124, G-CSF in 13/100; P=.11, Fisher's exact test), preterm labors (all pregnancies, no G-CSF in 9/124, G-CSF in 2/100, P=.12). A study with at least 300 per group would be needed to detect a difference in these events with 80% statistical power (alpha=0.05). Four newborns of mothers with idiopathic or autoimmune neutropenia not on G-CSF (4/101) had life-threatening infections, whereas there were no similar events (0/90) in the treated group, but this difference was also not statistically significant (P=.124). Adverse events in the neonates were similar for the two groups.

CONCLUSION: This observational study showed no significant adverse effects of administration of G-CSF to women with severe chronic neutropenia during pregnancy.

LEVEL OF EVIDENCE: III.

Rights and Permissions

Citation: Obstet Gynecol. 2015 Jan;125(1):197-203. doi: 10.1097/AOG.0000000000000602. Link to article on publisher's site

Related Resources

Link to Article in PubMed

PubMed ID

25560125